Edition:
United Kingdom

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

2.21USD
20 Jul 2018
Change (% chg)

$-0.02 (-0.90%)
Prev Close
$2.23
Open
$2.25
Day's High
$2.28
Day's Low
$2.20
Volume
14,977
Avg. Vol
27,486
52-wk High
$12.80
52-wk Low
$2.03

Chart for

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $28.03
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

Financials

  PTIE.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -1.98 -- --
ROI: -71.40 2.22 14.61
ROE: -71.40 3.86 16.34

BRIEF-Pain Therapeutics Q1 Loss Per Share $0.33

* PAIN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ON REMOXY® ER

09 May 2018

BRIEF-Pain Therapeutics Announces FDA Advisory Committee Meeting For Remoxy ER

* PAIN THERAPEUTICS ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY ER®

19 Mar 2018

BRIEF-FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018

* FDA ACCEPTS REMOXY® NDA FOR REVIEW, SETS PDUFA DATE OF AUGUST 7, 2018

01 Mar 2018

BRIEF-Pain Therapeutics Resubmits New Drug Application For Remoxy ER

* PAIN THERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR REMOXY® ER, AN ABUSE-DETERRENT, EXTENDED-RELEASE DRUG CANDIDATE FOR THE TREATMENT OF CHRONIC PAIN

13 Feb 2018

BRIEF-Pain Therapeutics Signs On Demand Sales Agreement With JonesTrading Institutional Services

* PAIN THERAPEUTICS SAYS ON FEB 8, CO ENTERED INTO AN ATM CAPITAL ON DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES LLC - SEC FILING

09 Feb 2018

BRIEF-Pain Therapeutics Inc QTRLY ‍Net Loss Per Share $0.37​

* PAIN THERAPEUTICS INC QTRLY ‍NET LOSS PER SHARE $0.37​ Source text: [http://bit.ly/2nGTz7J] Further company coverage:

05 Feb 2018

Competitors

Earnings vs. Estimates